Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

OpSens to Host Second Quarter Fiscal Year 2021 Financial Results Conference Call on Wednesday, April 14, 2021

Canada NewsWire

Conference call to be conducted at 11:00 am ET

QUEBEC CITY , April 6, 2021 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology, will report financial results for its second quarter of fiscal year 2021, ended February 28, 2021 on Wednesday, April 14, 2021 before the open of the market. The Company has scheduled a conference call the same day, at 11:00 am ET , to review the results.

OpSens Logo (CNW Group/OPSENS Inc.)

Interested parties can access the conference call by dialing (877) 270-2148 or (412) 902-6510 or can listen via a live Internet webcast, available in the Investors section of the Company's website at https://opsens.com/investors/ or at https://www.webcaster4.com/Webcast/Page/2512/40667 .

A teleconference replay of the call will be available for three days at (877) 344-7529 or (412) 317-0088, confirmation # 10154099. A webcast replay will be available in the Investors section of the Company's website at https://opsens.com/investors/ or at https://www.webcaster4.com/Webcast/Page/2512/40667 .

About OpSens Inc. ( www.OpSens.com or www.OpSensmedical.com )

OpSens focuses mainly on coronary artery stenosis measurement in interventional cardiology. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 100,000 patients in more than 30 countries. It is approved for sale in the United States , European Union, Japan , and Canada .

OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.

SOURCE OPSENS Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2021/06/c3726.html



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today